Results for tag: "Fragile X Syndrome"

Fragile X Syndrome (FXS) is a genetic disorder that is the most common inherited form of intellectual disability and the most common single-gene cause of autism. It is caused by a mutation in the FMR1 gene, which is located on the X chromosome. Symptoms of FXS can include intellectual disability, delayed speech and language development, anxiety, hyperactivity, and social and behavioral problems. The market for FXS is focused on treatments and therapies that can help manage the symptoms of the disorder. These treatments include medications, behavioral therapies, and educational interventions. There is also a growing focus on developing treatments that can target the underlying cause of the disorder. Companies in the FXS market include Roche, Novartis, and Biogen. Roche is developing a drug to treat FXS, while Novartis is researching gene therapy treatments. Biogen is researching a drug to treat the underlying cause of FXS. Show Less Read more